TNF and rheumatoid arthritis: An integrated analysis of three clinical trials demonstrated that ozoralizumab, an anti‐TNF nanobody, consistently maintained ACR20 response rates over a mean treatment duration of 200 weeks without introducing new safety concerns in RA patients [525].